CN114867723A - 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物 - Google Patents

作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物 Download PDF

Info

Publication number
CN114867723A
CN114867723A CN202180007608.5A CN202180007608A CN114867723A CN 114867723 A CN114867723 A CN 114867723A CN 202180007608 A CN202180007608 A CN 202180007608A CN 114867723 A CN114867723 A CN 114867723A
Authority
CN
China
Prior art keywords
degrees
formula
compound
pharmaceutical composition
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180007608.5A
Other languages
English (en)
Other versions
CN114867723B (zh
Inventor
付翔宇
李小庭
胡利红
房效娟
周晨晨
姚婷
吴松亮
丁照中
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Aosaikang Pharmaceutical Co Ltd
Original Assignee
Jiangsu Aosaikang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Aosaikang Pharmaceutical Co Ltd filed Critical Jiangsu Aosaikang Pharmaceutical Co Ltd
Publication of CN114867723A publication Critical patent/CN114867723A/zh
Application granted granted Critical
Publication of CN114867723B publication Critical patent/CN114867723B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了作为TGF‑βR1抑制剂药物的5‑(4‑吡啶氧基)吡唑类化合物的盐型、晶型、其制备方法以及药物组合物及其制备方法，具体公开了式(I)化合物的晶型、盐型及其晶型，还具体公开了包含式(I)化合物或其药学上可接受盐的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202180007608.5A 2020-07-23 2021-07-12 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物 Active CN114867723B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020107177614 2020-07-23
CN202010717761 2020-07-23
PCT/CN2021/105662 WO2022017208A1 (zh) 2020-07-23 2021-07-12 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物

Publications (2)

Publication Number Publication Date
CN114867723A true CN114867723A (zh) 2022-08-05
CN114867723B CN114867723B (zh) 2023-05-30

Family

ID=79728505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180007608.5A Active CN114867723B (zh) 2020-07-23 2021-07-12 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物

Country Status (2)

Country Link
CN (1) CN114867723B (zh)
WO (1) WO2022017208A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1951939A (zh) * 2001-05-24 2007-04-25 伊莱利利公司 作为药物的新的吡唑衍生物
WO2013086397A1 (en) * 2011-12-08 2013-06-13 Array Biopharma Inc. Urea compounds as gka activators
CN106795139A (zh) * 2014-10-07 2017-05-31 伊莱利利公司 氨基吡啶基氧基吡唑化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113316575B (zh) * 2019-01-24 2022-03-18 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1951939A (zh) * 2001-05-24 2007-04-25 伊莱利利公司 作为药物的新的吡唑衍生物
WO2013086397A1 (en) * 2011-12-08 2013-06-13 Array Biopharma Inc. Urea compounds as gka activators
CN106795139A (zh) * 2014-10-07 2017-05-31 伊莱利利公司 氨基吡啶基氧基吡唑化合物

Also Published As

Publication number Publication date
WO2022017208A1 (zh) 2022-01-27
CN114867723B (zh) 2023-05-30

Similar Documents

Publication Publication Date Title
TW202110836A (zh) 固態形式
WO2016023422A1 (zh) 2-(2,4,5-取代苯胺)嘧啶衍生物、其药物组合物及其用途
EP3254681B1 (en) N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt
EP3985000A1 (en) 2,4-disubstituted pyrimidine derivative, preparation method for same, and uses thereof
CN1898232B (zh) 用作抗血管发生剂的喹唑啉衍生物的马来酸盐
TW201735925A (zh) Ｃ-ｍｅｔ調節劑醫藥組合物
JP2008519049A (ja) 増殖性疾患の治療のためのｓｒｃキナーゼインヒビターおよびｂｃｒ−ａｂｌインヒビターの組み合わせ医薬
CN112010839B (zh) 靶向丝/苏氨酸激酶抑制剂的晶型
TW202208375A (zh) ４－胺基－５－（６－（４－甲基哌－１－基）－１ｈ－苯并［ｄ］咪唑－２－基）噻吩并［２，３－ｂ］吡啶－６（７ｈ）－酮之鹽及晶形
CN111548343B (zh) 一种高活性csf1r抑制剂化合物的制备方法
CA3224945A1 (en) Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
WO2018045993A1 (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
CN104540822B (zh) 达拉菲尼甲磺酸盐的晶型及其制备方法
CN116096713A (zh) 化合物的固体形式
WO2020244612A1 (zh) Cdk9抑制剂的多晶型物及其制法和用途
CN114867723A (zh) 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
CN116768856A (zh) 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
WO2020228729A1 (zh) 喹唑啉酮类化合物的晶型及其制备方法
CN113646312B (zh) 固体形式的brd4抑制剂化合物及其制备方法与应用
CA3098336C (en) Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
JP2023511675A (ja) アリールアミノプリン誘導体の塩、その調製方法ならびその用途
CN116171156A (zh) 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法
CN111848580B (zh) 含1,2,4-三嗪-3,5-二酮的喹啉类化合物的晶型及其制备方法和应用
WO2022016420A1 (zh) 一种喹唑啉酮类化合物的晶型、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant